Presentation of telomerase reverse transcriptase, a self-tumor antigen, is down-regulated by histone deacetylase inhibition

Cancer Research

Volumn 68, Issue 19, 2008, Pages 8085-8093

  Pellicciotta, Ilenia ^a   Cortez Gonzalez, Xochitl ^a   Sasik, Roman ^a   Reiter, Yoram ^b   Hardiman, Gary ^a   Langlade Demoyen, Pierre ^c   Zanetti, Maurizio ^a,d  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c INSTITUT PASTEUR   (France)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE; HLA A2 ANTIGEN; PROTEASOME; TAPASIN; TELOMERASE REVERSE TRANSCRIPTASE; TRICHOSTATIN A;

ANTIGEN PRESENTATION; ARTICLE; CD8+ T LYMPHOCYTE; CELL KILLING; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA MICROARRAY; DOWN REGULATION; ENZYME INHIBITION; GENETIC CODE; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; UNINDEXED SEQUENCE;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; AUTOANTIGENS; CD8-POSITIVE T-LYMPHOCYTES; CELL DEATH; DOWN-REGULATION; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; HISTONE DEACETYLASES; HLA-A2 ANTIGEN; HUMANS; HYDROXAMIC ACIDS; MEMBRANE TRANSPORT PROTEINS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEASOME ENDOPEPTIDASE COMPLEX; TELOMERASE; TUMOR CELLS, CULTURED;

EID: 54249111906     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1014     Document Type: Article

References (47)

1. Feinberg AP. Phenotypic plasticity and the epigenetics of human disease. Nature 2007;447:433-40.
2. Bird A. Perceptions of epigenetics. Nature 2007;447:396-8.
3. Polevoda B, Sherman F. N-terminal acetyltransferases and sequence requirements for N-terminal acetylation of eukaryotic proteins. J Mol Biol 2003;325:595-622.
4. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev 1999;9:40-8.
5. Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005;37:391-400.
6. Zou YR, Sunshine MJ, Taniuchi I, Hatam F, Killeen N, Littman DR. Epigenetic silencing of CD4 in T cells committed to the cytotoxic lineage. Nat Genet 2001;29:332-6.
7. Avni O, Lee D, Macian F, Szabo SJ, Glimcher LH, Rao A. T(H) cell differentiation is accompanied by dynamic changes in histone acetylation of cytokine genes. Nat Immunol 2002;3:643-51.
8. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005;436:1186-90.
9. Khan AN, Magner WJ, Tomasi TB. An epigenetically altered tumor cell vaccine. Cancer Immunol Immunother 2004;53:748-54.
10. Vonderheide RH, Hahn WC, Schultze JL, and Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999;10:673-9.
11. Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci U S A 2000;97:4796-801.
12. Finnin MS, Donigian JR, Cohen A, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999;401:188-93.
13. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33:787-91.
14. Filaci G, Fravega M, Setti M, et al. Frequency of telomerase-specific CD8+ T lymphocytes in cancer patients. Blood 2006;107:1505-12.
15. Lev A, Denkberg G, Cohen CJ, et al. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit. Cancer Res 2002;62:3184-94.
16. Yin L, Laevsky G, Giardina C. Butyrate suppression of colonocyte NF-n B activation and cellular proteasome activity. J Biol Chem 2001;276:44641-6.
17. Eberwine J, Yeh H, Miyashiro K, et al. Analysis of gene expression in single live neurons. Proc Natl Acad Sci U S A 1992;89:3010-4.
18. Sasik R, Woelk CH, Corbeil J. Microarray truths and consequences. J Mol Endocrinol 2004;33:1-9.
19. Takakura M, Kyo S, Sowa Y, et al. Telomerase activation by histone deacetylase inhibitor in normal cells. Nucleic Acids Res 2001;29:3006-11.
20. Cong YS, Bacchetti S. Histone deacetylation is involved in the transcriptional repression of hTERT in normal human cells. J Biol Chem 2000;275:35665-8.
21. Hou M, Wang X, Popov N, et al. The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells. Exp Cell Res 2002;274:25-34.
22. Mitsiades N, Mitsiades CS, Richardson PG, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003;101:4055-62.
23. Wheeler M, Rizzi M, Sasik R, et al. KDEL-retained antigen in B lymphocytes induces a pro-inflammatory response. A possible role for ER stress in adaptive T cell immunity. J Immunol 2008;181:256-64.
24. Cabrera CM. The double role of the endoplasmic reticulum chaperone tapasin in peptide optimization of HLA class I molecules. Scand J Immunol 2007;65:487-93.
25. Kim JH, Park SM, Kang MR, et al. Ubiquitin ligase MKRN1 modulates telomere length homeostasis through a proteolysis of hTERT. Genes Dev 2005;19:776-81.
26. Harding HP, Calfon M, Urano F, Novoa I, Ron D. Transcriptional and translational control in the Mammalian unfolded protein response. Annu Rev Cell Dev Biol 2002;18:575-99.
27. Howarth M, Williams A, Tolstrup AB, Elliott T. Tapasin enhances MHC class I peptide presentation according to peptide half-life. Proc Natl Acad Sci U S A 2004;101:11737-42.
28. Paulsson KM, Kleijmeer MJ, Griffith J, et al. Association of tapasin and COPI provides a mechanism for the retrograde transport of major histocompatibility complex (MHC) class I molecules from the Golgi complex to the endoplasmic reticulum. J Biol Chem 2002;277:18266-71.
29. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002;1:287-99.
30. Garbi N, Tan P, Diehl AD, et al. Impaired immune responses and altered peptide repertoire in tapasin-deficient mice. Nat Immunol 2000;1:234-8.
31. van Hall T, Wolpert EZ, van Veelen P, et al. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med 2006;12:417-24.
32. Purcell AW, Gorman JJ, Garcia-Peydro M, et al. Quantitative and qualitative influences of tapasin on the class I peptide repertoire. J Immunol 2001;166:1016-27.
33. Paulsson KM, Jevon M, Wang JW, Li S, Wang P. The double lysine motif of tapasin is a retrieval signal for retention of unstable MHC class I molecules in the endoplasmic reticulum. J Immunol 2006;176:7482-8.
34. Khan AN, Gregorie CJ, Tomasi TB. Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol Immunother 2008;57:647-54.
35. Zanetti M, Hernandez X, Langlade-Demoyen P. Telomerase reverse transcriptase as target for antitumor T cell responses in humans. Springer Semin Immunopathol 2005;27:87-104.
36. Masutomi K, Possemato R, Wong JM, et al. The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc Natl Acad Sci U S A 2005;102:8222-7.
37. d'Adda di Fagagna F, Teo SH, Jackson SP. Functional links between telomeres and proteins of the DNA-damage response. Genes Dev 2004;18:1781-99.
38. Burnet FM. Immunological surveillance in neoplasia. Transplant Rev 1971;7:3-25.
39. Delp K, Momburg F, Hilmes C, Huber C, Seliger B. Functional deficiencies of components of the MHC class I antigen pathway in human tumors of epithelial origin. Bone Marrow Transplant 2000;25 Suppl 2:S88-95.
40. Li J, Schuler-Thurner B, Schuler G, Huber C, Seliger B. Bipartite regulation of different components of the MHC class I antigen-processing machinery during dendritic cell maturation. Int Immunol 2001;13:1515-23.
41. Seliger B, Atkins D, Bock M, et al. Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. Clin Cancer Res 2003;9:1721-7.
42. Seliger B, Schreiber K, Delp K, et al. Downregulation of the constitutive tapasin expression in human tumor cells of distinct origin and its transcriptional upregulation by cytokines. Tissue Antigens 2001;57:39-45.
43. Seliger B, Wollscheid U, Momburg F, Blankenstein T, Huber C. Coordinate down-regul ation of multiple MHC class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin. Tissue Antigens 2000;56:327-36.
44. Seliger B, Wollscheid U, Momburg F, Blankenstein T, Huber C. Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res 2001;61:1095-9.
45. Armeanu S, Bitzer M, Lauer UM, et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005;65:6321-9.
46. Diermayr S, Himmelreich H, Durovic B, et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 2008;111:1428-36.
47. Wischnewski F, Pantel K, Schwarzenbach H. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res 2006;4:339-49.